Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95242 trials found · Page 161 of 4763
-
Artificial bronchus implant could be a lifeline for severe emphysema patients
Disease control Recruiting nowA study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.
Phase: NA • Sponsor: Pulmair Medical, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for pancreatic cancer: Immune-Reprogramming drug trial launches
Disease control Recruiting nowThe investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with g…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 16, 2026 18:38 UTC
-
New mRNA HIV vaccines enter human testing – could they teach the body to neutralize the virus?
⭐️ VACCINE ⭐️ Recruiting nowThis is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Bo…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 16, 2026 18:40 UTC
-
New combo therapy aims to shrink tough head and neck cancers
Disease control ENROLLING_BY_INVITATIONThis research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 16, 2026 18:41 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingTo evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining immunotherapy with ADC drugs in the neoadjuvant settin…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Can Pre-Surgery immunotherapy stop liver cancer from coming back?
Disease control Not yet recruitingOur study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor. HCC is the most prevalent primary liver cancer, responsible for nearly 800,000 deaths annually, m…
Phase: PHASE3 • Sponsor: University of Geneva, Switzerland • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control Not yet recruitingA Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New hope for rare liver disease: libevitug enters final trial phase
Disease control Not yet recruitingThis is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection. Eligible participants will be randomized 1:1:1 to one of three groups: libevitug 20 mg/kg g…
Phase: PHASE3 • Sponsor: Huahui Health • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo therapy aims to wipe out early TNBC before surgery
Disease control Not yet recruitingCamrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients Eligible Population 18-75-year-old female patients with n…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 16, 2026 18:41 UTC
-
Hope for Alzheimer's psychosis: new drug enters final testing phase
Symptom relief Recruiting nowThe purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated May 16, 2026 18:41 UTC
-
New radiation drug shows promise for Hard-to-Treat kidney cancer
Disease control Recruiting nowMulticenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX25…
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
AI and scans join forces to outsmart pancreatic cancer
Knowledge-focused Recruiting nowThis clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without sym…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 16, 2026 18:42 UTC
-
New stroke device aims to restore brain blood flow faster
Disease control Recruiting nowThis study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Sponsor: Imperative Care, Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for rare nerve disorder: drug trial targets underlying cause
Disease control Recruiting nowThe MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. An…
Phase: PHASE2 • Sponsor: Azienda Ospedaliera di Padova • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
Blood test could spare some breast cancer patients from extra drugs
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Bas…
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Brain pacemaker trial aims to tame severe childhood seizures
Disease control Recruiting nowThe CADET Trial will investigate the effectiveness of deep brain stimulation (DBS) to reduce the frequency of seizures in children with Lennox-Gastaut syndrome (LGS). The CADET Trial will use a non-CE/UKCA marked device - the Picostim DBS system. The SMART-DBS study is a sub-stu…
Phase: NA • Sponsor: University College, London • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Personalized heart procedure may beat standard treatment for AFib
Disease control Recruiting nowAtrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effe…
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug cocktail aims to boost lymphoma remission
Disease control Not yet recruitingPrimary Objective: To compare the complete response rate (CR rate) after induction treatment between the ZR2 regimen and the R2 regimen.\<br/\>\<br/\>Secondary Objectives: To compare the objective response rate (ORR) after induction treatment, progression-free survival (PFS), pro…
Phase: PHASE2 • Sponsor: KeshuZhou • Aim: Disease control
Last updated May 16, 2026 18:52 UTC
-
New drug cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThe study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
Phase: PHASE2, PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 18:41 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control Not yet recruitingThis is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radioth…
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 12, 2026 13:40 UTC